Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Enhancement of Hypericin Nanoparticle-Mediated Sonoinduced Disruption of Biofilm and Persister Cells of Streptococcus Mutans by Dermcidin-Derived Peptide Dcd-1L Publisher Pubmed



Pourhajibagher M1 ; Parker S2 ; Pourakbari B3, 4 ; Valian NK5 ; Raoofian R6 ; Bahador A7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Leicester School of Pharmacy, De Montfort University, Leicester, LE1 9BH, United Kingdom
  3. 3. Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Periodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
  7. 7. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Fellowship in Clinical Laboratory Sciences, BioHealth Lab, Tehran, Iran

Source: Photodiagnosis and Photodynamic Therapy Published:2023


Abstract

Background: Streptococcus mutans is considered a major significant contributor to dental caries and its effective removal is difficult due to the formation of biofilm. Therefore, the development of adjuvant therapeutic strategies with anti-biofilm properties is a promising approach. In the present study, we examined the effect of dermcidin-derived peptide DCD-1 L on the antibacterial activity of hypericin nanoparticle (HypNP)-mediated antimicrobial sonodynamic therapy (aSDT) against persister cells growing- and biofilm cultures of S. mutans. Materials and methods: Following synthesis and confirmation of HypNP, the fractional inhibitory concentration (FIC) index of HypNP and DCD-1 L was determined by checkerboard assay. Cellular uptake of HypNP-DCD-1 L and generation of endogenous reactive oxygen species (ROS) were assessed and followed by the determination of antimicrobial sonoactivity of HypNP-DCD-1 L against persister cells growing- and biofilm cultures of S. mutans. The water-insoluble extracellular polysaccharide (EPS) and expression of the gtfD, comDE, and smuT genes were then evaluated in persister cells growing- and biofilm cultures of S. mutans. Results: There was a synergistic activity in the combination of HypNP and DCD-1 L against S. mutans with an FIC index value of 0.37. The HypNP-DCD-1L-mediated aSDT also displayed the highest cellular uptake and endogenous ROS generation by bacterial cells. When biofilm and persister cells of S. mutans were treated with HypNP-DCD-1 L and subsequently exposed to ultrasound waves, 5.1 log and 3.8 log reductions, respectively, in bacterial numbers were observed (P<0.05). According to the data, EPS in both persister cells growing- and biofilm cultures of S. mutans were significantly decreased after exposure to the HypNP-DCD-1L-mediated aSDT (P<0.05). In addition, the quantitative real-time PCR data illustrated the high level of similarities in very low-expression profiles of the gtfD before and after all treated groups for persister cells. While, following HypNP-DCD-1L-mediated aSDT treatment, the expression levels of gtfD, comDE, and smuT were significantly lower in treated persister cells growing- and biofilm cultures of S. mutans in comparison with control groups (P<0.05). Conclusions: Combined, the results of this study indicate that ultrasound waves-activated HypNP-DCD-1 L can sonoinactivate S. mutans biofilms and persister cells, as well as reduce effectively pathogenicity potency of S. mutans. Hence, HypNP-DCD-1L-mediated aSDT may be proposed as a promising adjunctive therapeutic approach for dental caries. © 2023
Experts (# of related papers)
Other Related Docs
9. Staphylococcus Aureus Dormancy: Waiting for Insurgency, Current Pharmaceutical Biotechnology (2023)